Showing results (211-220 of 584) with videos related to
Sort By:
Pageof 59
Future Oncology (London, England)|February 17, 2025
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLCJohn V Heymach, Helena A Yu, Benjamin Besse, et al.JCO Precision Oncology|August 1, 2024
Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case ReportsLodovica Zullo, Elora Castanet, Zineb Maaradji, et al.Virchows Archiv : an International Journal of Pathology|January 16, 2013
Thymic carcinomas: clinicopathologic study of 37 cases from a single institutionVincent Thomas de Montpréville, Maria-Rosa Ghigna, Ludovic Lacroix, et al.Lung Cancer (Amsterdam, Netherlands)|October 1, 2011
Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meetingCesare Gridelli, Rolf Stahel, Benjamin Besse, et al.Molecular Oncology|April 10, 2012
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave RoussyMonica Arnedos, Fabrice André, Françoise Farace, et al.Bulletin Du Cancer|April 23, 2021
[Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]Reda El Hazzaz, Maria Kfoury, Pernelle Lavaud, et al.European Journal of Cancer (Oxford, England : 1990)|March 24, 2023
Biomarkers of response to immunotherapy in early stage non-small cell lung cancerMatthieu Roulleaux Dugage, Víctor Albarrán-Artahona, Juan Carlos Laguna, et al.Clinical Lung Cancer|June 7, 2016
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC StudyDavid Planchard, Takashi Yokoi, Michael J McCleod, et al.Journal for Immunotherapy of Cancer|June 14, 2020
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatmentMélanie Desbois, Coralie Béal, Mélinda Charrier, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 1, 2015
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patientsFayçal Djenidi, Julien Adam, Aïcha Goubar, et al.Pageof 59